secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncotelic Therapeutics, Inc. (OTLC)
CIK:        0000908259
Form:       8-K
Filed at:   2024-04-29T23:59:59+00:00
Accession:  0001493152-24-016839
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncotelic sells necroptosis cancer therapy assets to Mosaic for up to $30M
--------------------------------------------------------------------------

- Mosaic to issue $15M in shares at closing; Oncotelic may earn $15M more in cash/shares based on milestones.
- Transaction includes Oncotelic's CA4P clinical-stage necroptosis therapies and AI tech for immunotherapy combos.
- Mosaic to fund $2.0-$2.5M annual development budget; Oncotelic to loan short-term operational costs until June 1, 2024.
- If Oncotelic cannot help raise $2M for Mosaic, transaction may become reverse merger.
- Parties to negotiate definitive agreement; closing subject to customary due diligence.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/908259/000149315224016839/0001493152-24-016839-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/908259/000149315224016839/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-016839

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer